Sociodemographic and clinical cardiovascular risk factors and CHIP prevalence
Variable . | OR . | CI-low . | CI-high . | P value . | B-H threshold for significance . |
---|---|---|---|---|---|
Age | 1.07 | 1.05 | 1.09 | <.001 | NA, adjustment variable |
Male sex | 0.861 | 0.65 | 1.14 | .30 | NA, adjustment variable |
Current/former smoking | 1.37 | 1.14 | 1.66 | <.001 | NA, adjustment variable |
Calculated ASCVD risk | 1.00 | 0.95 | 1.05 | .96 | 0.06 |
Total cholesterol | 1.00 | 1.00 | 1.00 | .69 | 0.05 |
LDL-C | 1.00 | 1.00 | 1.00 | .80 | 0.06 |
HDL-C | 1 | 0.99 | 1.01 | .59 | 0.04 |
Diagnosis of hypertension | 1.14 | 0.88 | 1.49 | .32 | 0.03 |
Hypertension medication | 1.07 | 0.77 | 1.45 | .68 | 0.05 |
Lipid lowering therapy | 1.26 | 0.48 | 2.69 | .59 | 0.05 |
Hormonal contraceptive therapy | 0.36 | 0.09 | 0.97 | .08 | 0.03 |
Estrogen therapy | 0.26 | 0.01 | 1.19 | .18 | 0.03 |
Testosterone therapy | 2.02 | 1.11 | 4.04 | .066 | 0.02 |
Country group | |||||
High income North American countries | 1 | - | - | - | |
Latin America + Caribbean | 0.56 | 0.34 | 0.87 | .01 | 0.02 |
Sub-Saharan Africa | 0.57 | 0.4 | 0.81 | .002 | 0.01 |
South East/East Asia | 0.81 | 0.52 | 1.22 | .33 | 0.04 |
South Asia | 0.45 | 0.23 | 0.8 | .01 | 0.01 |
Ethnicity (collected in North America) | |||||
NonHispanic/Latino | 1 | - | - | - | |
Hispanic/Latino | 0.38 | 0.23 | 0.54 | .002 | 0.004 |
Variable . | OR . | CI-low . | CI-high . | P value . | B-H threshold for significance . |
---|---|---|---|---|---|
Age | 1.07 | 1.05 | 1.09 | <.001 | NA, adjustment variable |
Male sex | 0.861 | 0.65 | 1.14 | .30 | NA, adjustment variable |
Current/former smoking | 1.37 | 1.14 | 1.66 | <.001 | NA, adjustment variable |
Calculated ASCVD risk | 1.00 | 0.95 | 1.05 | .96 | 0.06 |
Total cholesterol | 1.00 | 1.00 | 1.00 | .69 | 0.05 |
LDL-C | 1.00 | 1.00 | 1.00 | .80 | 0.06 |
HDL-C | 1 | 0.99 | 1.01 | .59 | 0.04 |
Diagnosis of hypertension | 1.14 | 0.88 | 1.49 | .32 | 0.03 |
Hypertension medication | 1.07 | 0.77 | 1.45 | .68 | 0.05 |
Lipid lowering therapy | 1.26 | 0.48 | 2.69 | .59 | 0.05 |
Hormonal contraceptive therapy | 0.36 | 0.09 | 0.97 | .08 | 0.03 |
Estrogen therapy | 0.26 | 0.01 | 1.19 | .18 | 0.03 |
Testosterone therapy | 2.02 | 1.11 | 4.04 | .066 | 0.02 |
Country group | |||||
High income North American countries | 1 | - | - | - | |
Latin America + Caribbean | 0.56 | 0.34 | 0.87 | .01 | 0.02 |
Sub-Saharan Africa | 0.57 | 0.4 | 0.81 | .002 | 0.01 |
South East/East Asia | 0.81 | 0.52 | 1.22 | .33 | 0.04 |
South Asia | 0.45 | 0.23 | 0.8 | .01 | 0.01 |
Ethnicity (collected in North America) | |||||
NonHispanic/Latino | 1 | - | - | - | |
Hispanic/Latino | 0.38 | 0.23 | 0.54 | .002 | 0.004 |
Here the odds of CHIP after adjustment for age, sex and smoking status is presented. Age, sex, and smoking status were used as adjustment variables and were not incorporated as exploratory variables, and thus not adjusted for multiple comparisons. Statistically significant values after adjustment for multiple comparisons are highlighted in bold, and Benjamini-Hochberg significance thresholds are presented.
B-H, Benjamini-Hochberg adjustment for multiple comparisons; HDL-C, high density lipoprotein concentration; LDL-C, low density lipoprotein concentration.